ANGO ANGIODYNAMICS INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1275187 · Fiscal year ends 05/31
Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY-2.6%
TTM EPS YoY-1.3%
Revenue 3-yr CAGR-1.1%
Net income 3-yr CAGR—
Margins
Gross margin55.7%
Operating margin-11.2%
Net margin-10.1%
FCF margin0.4%
EBITDA margin-4.3%
Returns
ROE-19.2%
ROA-13.0%
ROIC (approx.)-21.4%
Asset turnover1.28x
Leverage & solvency
Liabilities / assets32.2%
Debt / equity0.00x
Current ratio2.40x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.11x
Accruals ratio-14.4%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-05-31 | FY20252025-05-31 | FY20242024-05-31 | FY20232023-05-31 | FY20222022-05-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $320.17M | $292.50M | $303.91M | $338.75M | $316.22M |
| Cost of revenue | $145.28M | $134.79M | $149.22M | $164.51M | $150.49M |
| Gross profit | $174.89M | $157.71M | $154.70M | $174.25M | $165.73M |
| R&D expense | $29.45M | $26.22M | $31.51M | $29.88M | $30.74M |
| SG&A expense | $43.69M | $42.09M | $41.16M | $40.00M | $38.45M |
| Operating income | -$39.93M | -$39.95M | -$192.44M | -$51.18M | -$28.47M |
| Interest expense | — | — | -$1.61M | $2.70M | $688,000 |
| Pretax income | -$36.30M | -$34.03M | -$191.64M | -$54.44M | -$29.95M |
| Income tax | $442,000 | -$39,000 | -$7.29M | -$2.00M | -$3.40M |
| Net income | -$36.74M | -$33.99M | -$184.35M | -$52.44M | -$26.55M |
| EBITDA | -$16.97M | -$14.15M | -$164.72M | -$20.31M | $878,000 |
| EPS (basic) | -0.88 | -0.83 | -4.59 | -1.33 | -0.68 |
| EPS (diluted) | -0.88 | -0.83 | -4.59 | -1.33 | -0.68 |
| Weighted avg. shares (diluted) | 41.53M | 40.85M | 40.18M | 39.48M | 39.01M |
| Balance sheet | |||||
| Cash & equivalents | $53.86M | $55.89M | $76.06M | $44.62M | $28.82M |
| Receivables | $48.33M | $42.89M | $43.61M | $52.83M | $52.30M |
| Inventory | $52.44M | $62.01M | $60.62M | $55.33M | $51.39M |
| Current assets | $163.39M | $168.32M | $193.25M | $163.54M | $143.34M |
| PP&E, net | $27.10M | $32.30M | $35.67M | $44.38M | $45.01M |
| Goodwill | — | — | $0 | $159.24M | $201.06M |
| Intangibles | $67.21M | $69.12M | $77.38M | $111.14M | $152.38M |
| Total assets | $267.16M | $280.14M | $317.67M | $532.64M | $552.75M |
| Current liabilities | $74.72M | $76.20M | $91.16M | $83.83M | $74.32M |
| Long-term debt | — | — | $0 | $49.82M | $25.00M |
| Total debt | — | — | $0 | $49.82M | $25.00M |
| Total liabilities | $96.34M | $97.17M | $112.08M | $154.34M | $128.26M |
| Shareholders' equity | $170.82M | $182.97M | $205.59M | $378.30M | $424.49M |
| Net debt | — | — | -$76.06M | $5.20M | -$3.83M |
| Shares outstanding | 41.70M | 40.99M | 40.43M | 39.61M | 39.17M |
| Cash flow statement | |||||
| Operating cash flow | $3.09M | -$10.13M | -$28.16M | $78,000 | -$7.19M |
| Capital expenditure | $2.58M | $4.46M | $2.52M | $3.81M | $4.30M |
| Free cash flow | $508,000 | -$14.59M | -$30.68M | -$3.73M | -$11.49M |
| Investing cash flow | -$5.95M | -$10.18M | $123.72M | -$9.75M | -$19.31M |
| Financing cash flow | $564,000 | -$255,000 | -$64.25M | $25.42M | $7.68M |
| Depreciation & amortization | $22.95M | $25.80M | $27.71M | $30.87M | $29.35M |
| Stock-based compensation | $13.96M | $9.77M | $10.53M | $11.16M | $10.69M |
| Share buybacks | $0 | $1.67M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.